Zachary Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zachary Lee has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Abraham Sachs
Department of Surgery, Albany Medical College, Albany, NY 12208, USA
1 shared publication - Divya Mohanraj
Department of Surgery, Albany Medical College, Albany, NY 12208, USA
1 shared publication - Madhavi Kambam
New York Hematology and Oncology, Albany, NY 13057, USA
1 shared publication - Sandra R. DiBrito
Albany Medical Center, Department of Surgery, 43 New Scotland Avenue, Albany, NY 12208, USA
1 shared publication
Latest Publications
- Open Access
- 21 June 2024
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 4 (3) , 387-401
Current Practice in the Diagnosis and Treatment of Localized Gastric Gastrointestinal Stromal Tumors
Gastric gastrointestinal stromal tumors (GIST) are rare, neuroectodermal tumors primarily residing in the stomach with characteristic genetic mutations. They are often identified using ultrasound and cross-sectional imaging, or they are noted during endoscopy. Localized gastric GISTs are commonly treated with surgical resection, with the possible use of neoadjuvant or adjuvant medical therapies as they are considered to have malignant potential. The use of tyrosine kinase inhibitors (TKI) such as imatinib has been shown to successfully reduce pre-operative tumor burden, recurrence, and disease progression. Surgical resection considerations vary depending on tumor size, location, and malignant potential. Neoadjuvant and adjuvant TKI therapy dosing varies in response to the type of GIST mutation present and greatly influences prognosis. Novel cooperative minimally invasive surgical techniques and targeted therapies are currently in development to address challenges in GIST treatment for tumors in challenging locations or with significant potential for progression. The management of localized gastric GISTs continues to rapidly evolve; each case should be managed individually, where care is taken in considering details, including tumor location, tumor size, and the molecular genetic profile, before embarking on a course of treatment.
- 21 June 2024
- Published by MDPI AG in International Journal of Translational Medicine
- Vol. 4 (3) , 387-401
Open AccessCurrent Practice in the Diagnosis and Treatment of Localized Gastric Gastrointestinal Stromal Tumors
Gastric gastrointestinal stromal tumors (GIST) are rare, neuroectodermal tumors primarily residing in the stomach with characteristic genetic mutations. They are often identified using ultrasound and cross-sectional imaging, or they are noted during endoscopy. Localized gastric GISTs are commonly treated with surgical resection, with the possible use of neoadjuvant or adjuvant medical therapies as they are considered to have malignant potential. The use of tyrosine kinase inhibitors (TKI) such as imatinib has been shown to successfully reduce pre-operative tumor burden, recurrence, and disease progression. Surgical resection considerations vary depending on tumor size, location, and malignant potential. Neoadjuvant and adjuvant TKI therapy dosing varies in response to the type of GIST mutation present and greatly influences prognosis. Novel cooperative minimally invasive surgical techniques and targeted therapies are currently in development to address challenges in GIST treatment for tumors in challenging locations or with significant potential for progression. The management of localized gastric GISTs continues to rapidly evolve; each case should be managed individually, where care is taken in considering details, including tumor location, tumor size, and the molecular genetic profile, before embarking on a course of treatment.